Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company focusing on genetically defined rare diseases, announced participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 9:20 a.m. ET. A live audio webcast will be available on their investor relations website, with an archived replay accessible for 30 days. Fulcrum's lead programs include losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 targeting sickle cell disease.

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference, on Thursday, February 17, 2022 at 9:20 a.m. ET.

A live audio webcast will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. An archived replay will be available on the Company’s website for 30 days.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.

Please visit www.fulcrumtx.com.

Contact:

Investors:
Christi Waarich
Director, Investor Relations
cwaarich@fulcrumtx.com 
617-651-8664

FAQ

What is the date of Fulcrum Therapeutics' participation in the SVB Leerink Global Healthcare Conference?

Fulcrum Therapeutics will participate in the conference on February 17, 2022.

At what time is Fulcrum Therapeutics scheduled to speak at the conference?

The management of Fulcrum Therapeutics is scheduled to speak at 9:20 a.m. ET.

Where can I access the live webcast of Fulcrum Therapeutics' conference participation?

The live audio webcast can be accessed through the Investor Relations section of the Fulcrum Therapeutics website.

What are the lead programs of Fulcrum Therapeutics in clinical development?

Fulcrum's lead programs are losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.

How long will the archived replay of the conference be available?

The archived replay will be available on Fulcrum's website for 30 days.